Gossamer Bio, Inc. (GOSS) 8-K Current Report: February 23, 2026
Filed: February 23, 2026
Health Care
Pharmaceutical PreparationsGossamer Bio, Inc. (GOSS) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Gossamer Bio, Inc. 8-K Feb 23, 2026 Event Analysis
Item 8.01 · Other Events
- • Phase 3 PROSERA missed primary endpoint: p=0.0320 failed prespecified α=0.025 threshold; seralutinib showed +13.3m 6MWD improvement vs placebo but statistical bar not cleared
- • Strong signal in intermediate/high-risk subgroup (n=234, ~60% of trial): +20.0m placebo-adjusted 6MWD gain (p=0.0207); 3 of 4 key secondaries below p=0.0125
- • NT-proBNP (cardiac stress biomarker) sharply favored seralutinib: -120.4 ng/L vs placebo in overall population (p=0.0002); effect visible as early as Week 4
- • CTD-PAH subgroup showed strongest effect: +37.0m placebo-adjusted 6MWD gain (p=0.0104, n=87) — potentially a viable label target
- • FDA meeting planned to explore regulatory path forward; SERANATA trial enrollment paused pending review — approval timeline and company viability now highly uncertain
Other Gossamer Bio, Inc. 8-K Filings
Get deeper insights on Gossamer Bio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.